Clinical Trials Sponsored by Amphia Hospital

Total 101676 results

Ampio Pharmaceuticals. Inc.

Completed

A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

Covid19

United States
Mina Alpha Limited

Active, not recruiting

A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (TIMEPOINT)

Solid Tumor, Adult

United Kingdom
Zeno Alpha Inc.

Completed

A Study of ZN-c5 in Subjects With Breast Cancer

Breast Cancer

United States, Belarus, Bosnia and Herzegovina, Czechia, Hungary, Lithuania, Russian Federation, Serbia, Ukraine
Ampio Pharmaceuticals. Inc.

Completed

A Study to Evaluate Safety of Three Intra-articular Injections of Ampion in the Knee of Adults With Osteoarthritis Pain

Osteoarthritis of the Knee

United States
Ampio Pharmaceuticals. Inc.

Completed

AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint

Osteoarthritis of the Hand

United States
Alpha-1 Foundation

Completed

Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) (PFT)

Chronic Obstructive Pulmonary Disease | Alpha-1 Antitrypsin Deficiency

United States, Puerto Rico
Mina Alpha Limited

Active, not recruiting

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2)

Hepatitis B | Hepatocellular Carcinoma | Hepatitis C

Singapore, United States
Ampio Pharmaceuticals. Inc.

Terminated

A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

Covid19

United States
Zeno Alpha Inc.

Completed

A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

Breast Cancer

United States, Poland
Ampio Pharmaceuticals. Inc.

Completed

A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema.

Diabetic Macular Edema
Ampio Pharmaceuticals. Inc.

Terminated

Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee

Severe Osteoarthritis of the Knee

United States
Ampio Pharmaceuticals. Inc.

Completed

A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis

Osteoarthritis of the Knee

United States
Ampio Pharmaceuticals. Inc.

Completed

A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee

Osteoarthritis of the Knee

United States
Ampio Pharmaceuticals. Inc.

Completed

A Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee

Osteoarthritis of the Knee
Zeno Alpha Inc.

Completed

A Study of ZN-c5 in Participants With Breast Cancer

Breast Cancer

United States, Australia, Bosnia and Herzegovina
Ampio Pharmaceuticals. Inc.

Completed

An Efficacy and Safety Study of Two Doses of Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee

Osteoarthritis of the Knee
National and Kapodistrian University of Athens
University of Thessaly; Aghia Sophia Children's Hospital of Athens; National... and other collaborators

Completed

Efficacy of Pythagorean Self-Awareness for Aging Biomarkers Improvement, in T2D Patients and Healthy Individuals.

Type 2 Diabetes Mellitus | Telomere Shortening

Greece
Alpha-1 Foundation

Recruiting

Alpha-1 Research Registry

Alpha 1-Antitrypsin Deficiency

United States
Mina Alpha Limited

Active, not recruiting

First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH)

Hepatocellular Carcinoma | Liver Cancer

Taiwan, Singapore, United Kingdom
Ampio Pharmaceuticals. Inc.

Terminated

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

COVID-19

United States
Ampio Pharmaceuticals. Inc.

Terminated

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

Severe Osteoarthritis of the Knee

United States
Ampio Pharmaceuticals. Inc.

Completed

AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

Knee Osteoarthritis | Osteoarthritis, Knee | Knee Arthritis | Knee Pain Chronic

United States
Ampio Pharmaceuticals. Inc.

Completed

Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress

Covid19

United States
Ampio Pharmaceuticals. Inc.

Completed

Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation

COVID-19

United States
Zeno Alpha Inc.

Completed

A Food Effect Study With ZN-c5 in Healthy Post-Menopausal Subjects

Healthy

New Zealand
Leiden University Medical Center
Catharina Ziekenhuis Eindhoven; Medical Center Haaglanden; Haga Hospital; Jeroen... and other collaborators

Unknown

Anastomotic Leakage and Value Of Indocyanine Green in Decreasing Leakage Rates (AVOID)

Crohn Disease | Colo-rectal Cancer | Resectable Colorectal Carcinoma

Netherlands
Gwendolyn Vuurberg
Zimmer Biomet; Albert Schweitzer Hospital; Centro Hospitalar do Porto; Amphia Hospital and other collaborators

Recruiting

Chronic Ankle Instability, Surgical Repair: Open Versus Closed (CAISR)

Chronic Ankle Instability

Netherlands, Portugal, Switzerland
Laboratorios Sophia S.A de C.V.

Not yet recruiting

Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF

Ocular Surface Disease | Dry Eye Disease
Laboratorios Sophia S.A de C.V.

Not yet recruiting

Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PRO-232)

Healthy
Laboratorios Sophia S.A de C.V.

Recruiting

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PRO-169)

Diabetic Macular Edema

Colombia, Mexico
Omphis Foundation
Universitat de Lleida

Suspended

Study of the Influence of POLD Manual Therapy in Fibromyalgia

Fibromyalgia

Spain
Laboratorios Sophia S.A de C.V.

Completed

Phase IV Clinical Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. (PRO-087)

Dry Eye

Mexico
Laboratorios Sophia S.A de C.V.

Withdrawn

Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution (PRO-230)

Myopia
Laboratorios Sophia S.A de C.V.

Terminated

Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PRO-122)

Ocular Hypertension | Glaucoma, Open-Angle

Mexico
Amelia Adcock

Completed

TMS for Post Stroke Depression

Post-stroke Depression

United States
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® (PRO-122/I)

Glaucoma

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK) (CONFORTK)

Primary Open Angle Glaucoma | Ocular Hypertension
Laboratorios Sophia S.A de C.V.

Completed

Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide

Primary Open Angle Glaucoma | Ocular Hypertension

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects (PRO-087/I)

Dry Eye Syndromes | Lubricant Allergy | Tear Disorder

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome (PRO-148)

Dry Eye Syndrome

Mexico
Laboratorios Sophia S.A de C.V.

Withdrawn

Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers. (PRO-143)

Conjunctivitis, Bacterial

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Phase IV Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy (PRK) (PRO-037)

Photorefractive Keratectomy | Corneal De-epithelialization

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Clinical Study to Evaluate the Safety of the Viscoelastic Substance PRO-149 When Used During Phacoemulsification, Compared to Healon® EndoCoat. (PRO-149)

Age-related Cataract | Phacoemulsification

Mexico
Laboratorios Sophia S.A de C.V.

Terminated

Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. (PRO-157)

Conjunctivitis, Bacterial

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® (PRO-179/I)

Glaucoma

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo. (PRO-155/IV)

Ocular Inflammation | Ocular Pain | Pterygium | Post-surgical Inflammation

Mexico
Laboratorios Sophia S.A de C.V.

Terminated

Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension (COMPLIANCE)

Primary Open Angle Glaucoma | Ocular Hypertension

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers. (PRO-155)

Inflammation | Cataract

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) (Pazufloxacin)

Bacterial Conjunctivitis

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification

Cataract | Phacoemulsification Cataract Surgery

Mexico

3

Subscribe